Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Chronic obstructive pulmonary disease

Triple therapy cuts exacerbations in COPD regardless of baseline reversibility

Research presented at the CHEST annual meeting shows that triple therapy with fluticasone furoate, umeclidinium and vilanterol reduces the number of moderate-to-severe exacerbations for people living with chronic obstructive pulmonary disease.

Triple therapy reduces the number of moderate-to-severe exacerbations in people with chronic obstructive pulmonary disease (COPD), regardless of whether their airway obstruction is bronchodilator-reversible, a study presented at the CHEST annual meeting (6–10 October 2018; San Antonio, Texas) has shown[1].

The 52-week trial involved 10,355 people with COPD with a history of moderate-to-severe exacerbations in the previous 12 months. They were randomly assigned to triple therapy with inhaled corticosteroid fluticasone furoate (FF)/long-acting muscarinic agonist (LAMA) umeclidinium (UMEC)/long-acting beta-agonist (LABA) vilanterol (VI) or dual therapy with FF/VI or UMEC/VI. Patients were tested at baseline for airway obstruction reversibility with salbutamol and defined as either reversible (18%) or non-reversible (82%). 

The researchers found that the rate of moderate-to-severe exacerbations was reduced by 40% in reversible patients and by 21% in non-reversible patients with triple therapy, compared with UMEC/VI dual therapy. Severe exacerbations were reduced by 44% and 31%, respectively.

Moderate-to-severe exacerbations were also significantly reduced compared with FF/VI in both reversible and non-reversible patients. Although, FF/UMEC/VI did not reduce the rate of severe exacerbations over FF/VI in reversible patients.

International guidelines recommend dual therapy (LABA/LAMA) for most patients with COPD, with the addition of inhaled corticosteroids only for those with frequent exacerbations. It was previously uncertain whether baseline reversibility, which indicates whether patients are bronchodilator-responsive, affects treatment response to triple therapy.

“Regardless of baseline reversibility, [triple therapy] showed statistically significant and clinically relevant improvements on a range of important outcomes,” the researchers concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205754

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Minor Illness or Major Disease

    Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £43.00Buy now
  • Hospital Pre-registration Pharmacist Training

    Hospital Pre-registration Pharmacist Training

    A practical explanation for undergraduates and pre-registration trainees. Shows what to expect from a hospital pre-registration pharmacist training programme.

    £25.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.